Back to top
more

Inogen (INGN)

(Real Time Quote from BATS)

$5.95 USD

5.95
165,086

-0.35 (-5.56%)

Updated Aug 7, 2025 02:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?

by Zacks Equity Research

Medtronic (MDT) poised to gain on continued growth in RTG business in Q1.

    Zacks Equity Research

    Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?

    by Zacks Equity Research

    Medtronic (MDT) poised to gain on strength in Diabetes business in Q1 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.

      Zacks Equity Research

      Haemonetics Strong on Plasma Unit Amid Blood Center Weakness

      by Zacks Equity Research

      Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.

        Zacks Equity Research

        Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure

        by Zacks Equity Research

        Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.

          Zacks Equity Research

          Hologic Launches Fluent Fluid Management System, Widens Suite

          by Zacks Equity Research

          Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.

            Zacks Equity Research

            CVS Health's PBM Selling Season Strong, Aetna Deal on Track

            by Zacks Equity Research

            A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.

              Zacks Equity Research

              Amedisys (AMED) Grows on Robust Home Health, Personal Care

              by Zacks Equity Research

              Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.

                Zacks Equity Research

                Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?

                by Zacks Equity Research

                Is (INGN) Outperforming Other Medical Stocks This Year?

                  Zacks Equity Research

                  Here's Why You Should Invest in Align Technology (ALGN) Now

                  by Zacks Equity Research

                  We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.

                    Zacks Equity Research

                    AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology

                    by Zacks Equity Research

                    AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.

                      Zacks Equity Research

                      Wright Medical Strong Overseas, Back Order Issues Persist

                      by Zacks Equity Research

                      Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.

                        Zacks Equity Research

                        Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm

                        by Zacks Equity Research

                        Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.

                          Zacks Equity Research

                          Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children

                          by Zacks Equity Research

                          Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.

                            Zacks Equity Research

                            Integra LifeSciences Codman Arm Strong, Competition Rife

                            by Zacks Equity Research

                            Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.

                              Zacks Equity Research

                              Inogen's Solid Europe Business Shapes Q2, Prospects Bright

                              by Zacks Equity Research

                              Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.

                                Zacks Equity Research

                                Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes

                                by Zacks Equity Research

                                Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.

                                  Zacks Equity Research

                                  Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid

                                  by Zacks Equity Research

                                  Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.

                                    Zacks Equity Research

                                    Boston Scientific to Expand Within PI Via VENITI Buyout

                                    by Zacks Equity Research

                                    Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.

                                      Zacks Equity Research

                                      Becton, Dickinson Global Foothold Strong, Recalls Rampant

                                      by Zacks Equity Research

                                      Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.

                                        Zacks Equity Research

                                        Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now

                                        by Zacks Equity Research

                                        DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.

                                          Zacks Equity Research

                                          Here's Why You Should Hold on to Ecolab (ECL) Stock Now

                                          by Zacks Equity Research

                                          Ecolab (ECL) is likely to gain from a robust product portfolio, new product launches and expanding customer base.

                                            Zacks Equity Research

                                            Varian Acquires humediQ, Boosts Motion Management Portfolio

                                            by Zacks Equity Research

                                            Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.

                                              Zacks Equity Research

                                              Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance

                                              by Zacks Equity Research

                                              Inogen (INGN) puts up solid segmental show in Q2; international sales surge.

                                                Zacks Equity Research

                                                Inogen (INGN) Q2 Earnings and Revenues Top Estimates

                                                by Zacks Equity Research

                                                Inogen (INGN) delivered earnings and revenue surprises of 47.73% and 19.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                                                  Zacks Equity Research

                                                  RTIX or INGN: Which Is the Better Value Stock Right Now?

                                                  by Zacks Equity Research

                                                  RTIX vs. INGN: Which Stock Is the Better Value Option?